O ensaio principal, publicado recentemente na revista New England Journal of Medicine, mostrou uma diminuição relevante dos eventos adversos graves nas extremidades após a angioplastia com MagicTouch ao ano de seguimento, em comparação com o tratamento "ou com um balão sem recobrimento". Este novo subanálise, que inclui 597 pacientes com doença femoropoplítea sem perda de tecido, trará dados chave sobre uma coorte de grande interesse clínico, na qual os objetivos da revascularização não se limitam a preservar a extremidade, mas também buscam um alívio sustentado dos sintomas.
"The results will be presented by Prof. Dr. Stefano Barco (Co-PI) as part of the late-breaking clinical trial program at VIVA 2026, one of the leading international meetings dedicated to peripheral vascular disease and endovascular therapy."
Sobre o ensaio SirPAD
"SirPAD Trial is an academic, investigator initiated RCT comparing Sirolimus Coated Balloon (MagicTouch PTA) against uncoated balloon treatment in patients with femoropopliteal or below-the-knee disease. The trial enrolled 1,252 patients with the primary outcome published in the New England Journal of Medicine, indicating that treatment with Sirolimus Coated Balloon arm was both non-inferior and superior against uncoated balloon in terms of MALE."
Acerca de Concept Medical
"Concept Medical Group develops innovative drug-delivery technologies for coronary and peripheral vascular interventions. The company is the developer of MagicTouch PTA, the sirolimus-coated balloon evaluated in the SirPAD randomized trial."
"Si deseja mais informações: www.conceptmedical.com"
"View original content to download multimedia:https://www.prnewswire.com/news-releases/estudio-en-viva-2026---enfermedad-arterial-periferica-eap-femoropoplitea-en-pacientes-con-claudicacion-302884645.html"